Mike Israetel achieved an exceptional body transformation from 15.6% to 6% body fat in just over four months while building lean muscle, documented with DEXA scans
semaglutide: Key differences The following AOD 9604 vs
The role of the gut microbiota in dietary interventions for depression and anxiety
Sponsors should note that MFDS fees have increased to fund specialised reviewers and that a dedicated team will stay with a product from the first consultation through final approval
Limited case reports of accidental first-trimester exposure did not report severe adverse outcomes, but extended use carries greater theoretical risk
Key Takeaways Foundayo (orforglipron) is the first oral GLP-1 receptor agonist that can be taken any time of day without food or water restrictions FDA approved April 1, 2026 for chronic weight management Average weight loss in the ATTAIN-1 trial was 11.2% at 72 weeks at the highest dose less than injectable Wegovy (14.9%) or Zepbound (20.2%) Its small-molecule structure allows consistent absorption regardless of what is in the stomach Side effect profile is similar to other GLP-1 medications primarily gastrointestinal Starting cost is approximately $25/month with commercial insurance + Lilly savings card, $149/month self-pay for the lowest dose Best suited for patients with needle aversion, complicated schedules, or those who struggled with oral Wegovys fasting requirements Not recommended for patients already responding well to injectable GLP-1s Cannot be combined with other GLP-1 medications References Eli Lilly and Company
